New Tetracycline Antibiotic Shows Promise in Children With Lung Infections

A first-of-its-kind real-world study has reported that omadacycline, the newest member of the tetracycline class of antibiotics, produced favorable clinical outcomes in children and adolescents treated for bacterial infections, most of them in the lungs. The retrospective cohort, published in BMC Infectious Diseases, is the first study to document the use of this broad-spectrum drug in pediatric patients, a population in which the antibiotic had never been formally evaluated before. With 267 patients aged 8 to 17 years included from routine hospital care, the findings offer the earliest systematic glimpse of how this modern tetracycline performs in young bodies fighting serious bacterial disease.

Omadacycline belongs to the aminomethylcycline subclass, the latest generation of tetracycline derivatives, engineered to overcome the two major resistance mechanisms that disable older tetracyclines: efflux pumps that expel the drug from bacterial cells and ribosomal protection proteins that shield the drug’s binding site. Because of these modifications, omadacycline retains activity against methicillin-resistant Staphylococcus aureus, penicillin-resistant Streptococcus pneumoniae, and many gram-negative pathogens, which is precisely why clinicians have been eager to see it deployed against difficult infections. Until now, however, its approved indications covered adults with community-acquired bacterial pneumonia and acute bacterial skin infections, leaving pediatric use essentially uncharted territory.

The research team, led by pharmacists at the First Affiliated Hospital of Nanchang University in Jiangxi, China, combed electronic medical records for patients aged 8 to 17 who received omadacycline for infectious diseases. The retrospective design means the drug was given at the discretion of treating physicians in real clinical practice, not under the controlled conditions of a randomized trial. Clinical effectiveness was assessed on the day before discharge and graded on a four-point scale: cured, markedly effective, improved, or ineffective. Effective outcomes were defined as complete resolution or significant improvement of infection-related symptoms and signs without the need for additional antimicrobial therapy.

The headline result was striking. Of the 267 patients, 20, or 7.5 percent, were cured, 109, or 40.8 percent, were markedly effective, and 115, or 43.1 percent, were improved, adding up to a clinical effective rate of 91.4 percent. Only 23 patients, or 8.6 percent, failed to respond. In other words, roughly nine out of ten children and adolescents treated with omadacycline left the hospital with their infections resolved or substantially improved, without needing rescue antibiotics. For a drug never before documented in this age group, the aggregate outcome pattern closely mirrors what adult trials and real-world adult series have reported.

Statistical analysis revealed which factors tipped the balance toward success. Patients with pulmonary infection were significantly more likely to achieve effective outcomes than those with infections at other sites, with the difference reaching statistical significance at P equal to 0.012. A longer duration of combination therapy, in which omadacycline was given alongside other antibiotics, was also associated with a greater probability of effectiveness, at P equal to 0.030. The authors suggest that the drug’s strong lung penetration, a hallmark of the aminomethylcyclines, may partly explain the pulmonary advantage, while combination regimens may have provided broader initial coverage in severely ill children until pathogens were identified.

One of the most clinically useful findings concerned fever. Body temperature declined continuously after the medication was started, a trend that was highly significant across the treatment period at P less than 0.001. When the researchers compared the effective group with the ineffective group, the children who ultimately responded had significantly lower body temperatures on day 3, at P equal to 0.035, and day 4, at P equal to 0.002, after the medication began. This defervescence pattern could eventually serve as an early bedside signal, allowing clinicians to distinguish responders from non-responders within the first few days of therapy and adjust treatment before the infection gains further ground.

Safety was the other half of the equation, and here the short-term picture was reassuring. Only 5 patients developed mild liver injury after receiving the drug, and no moderate or severe liver injury was recorded anywhere in the cohort. Laboratory indices from routine blood examinations, including white blood cells, neutrophils, lymphocytes, and platelets, as well as liver function markers such as alanine transaminase, aspartate aminotransferase, total bilirubin, and direct bilirubin, and renal function measures including uric acid, all remained within normal ranges before and after treatment, and the observed changes lacked clinical significance. For a tetracycline-class drug, a class historically associated with photosensitivity, tooth discoloration, and gastrointestinal upset in children, this laboratory profile is a notable point in the drug’s favor.

The study was conducted in accordance with the Declaration of Helsinki, approved by the Ethics Committee of the First Affiliated Hospital of Nanchang University, and carried out with a waiver of informed consent given its retrospective design. Funding came from the National Natural Science Foundation of China and the Natural Science Foundation of Jiangxi Province. The authors declared no competing interests, and the article is published open access under a Creative Commons license, making the full dataset description and supplementary materials freely available to clinicians and researchers worldwide.

Yet the authors are careful about what these results can and cannot prove. A retrospective cohort cannot eliminate selection bias, since physicians chose omadacycline for particular patients for particular reasons, and the absence of a control group means the outcomes cannot be attributed to the drug with certainty. The pediatric population studied was also limited to children aged 8 and above, leaving younger children entirely unstudied. The authors explicitly state that prospective controlled studies are needed to confirm the findings before omadacycline can be considered an evidence-based option for pediatric infections.

Even with those caveats, the study marks a meaningful step in pediatric antimicrobial therapy. As multidrug-resistant bacteria continue to erode the utility of older antibiotics, every new agent that can be safely extended to children expands the therapeutic arsenal for the most vulnerable patients. If prospective trials bear out the 91.4 percent effective rate and the clean short-term safety profile reported here, omadacycline could become a valuable option for children with pneumonia caused by resistant pathogens, and the defervescence signature identified in this cohort may give clinicians an early, practical tool for judging whether the drug is working. For now, the message is one of cautious optimism: the newest tetracycline has taken its first documented steps in pediatric medicine, and the early results look promising.

Subject of Research: Infectious Diseases

Article Title: Omadacycline in pediatric patients with predominantly pulmonary infections: a retrospective, real-world study

Article References: Liu, J., Liu, J., Zhang, Z., Huang, J., Liu, J., & Ouyang, A. (2026). Omadacycline in pediatric patients with predominantly pulmonary infections: a retrospective, real-world study. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14317-z

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14317-z

Keywords: omadacycline, tetracycline, pediatrics, pulmonary infection, antibiotics, antimicrobial resistance, BMC Infectious Diseases, pediatric, patients, predominantly, pulmonary, infections